Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
Nivolumab Plus Ipilimumab Versus Sunitinib in First-Line Treatment for Advanced Renal Cell Carcinoma: Extended Follow-Up of Efficacy and Safety Results From a Randomised, Controlled, Phase 3 TrialLancet Oncol 2019 Aug 16;[EPub Ahead of Print], RJ Motzer, BI Rini, DF McDermott, O Arén Frontera, HJ Hammers, MA Carducci, P Salman, B Escudier, B Beuselinck, A Amin, C Porta, S George, V Neiman, S Bracarda, SS Tykodi, P Barthélémy, R Leibowitz-Amit, ER Plimack, SF Oosting, B Redman, B Melichar, T Powles, P Nathan, S Oudard, D Pook, TK Choueiri, F Donskov, MO Grimm, H Gurney, DYC Heng, CK Kollmannsberger, MR Harrison, Y Tomita, I Duran, V Grünwald, MB McHenry, S Mekan, NM Tannir
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Renal Cell Carcinoma Center of Excellence
Visit our Renal Cell Carcinoma Center of Excellence for additional, in-depth coverage.